Cargando…

COVID-19 in Colombia endpoints. Are we different, like Europe?

The infection by the new coronavirus (SARS-CoV-2) has taken the dimension of a pandemic, affecting more than 160 countries in a few weeks. In Colombia, despite the implementation of the rules established by the national government, exists an elevate concern both for mortality and for the limited cap...

Descripción completa

Detalles Bibliográficos
Autores principales: Amariles, Pedro, Granados, Johan, Ceballos, Mauricio, Montoya, Carlos Julio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7118674/
https://www.ncbi.nlm.nih.gov/pubmed/32265115
http://dx.doi.org/10.1016/j.sapharm.2020.03.013
_version_ 1783514609543544832
author Amariles, Pedro
Granados, Johan
Ceballos, Mauricio
Montoya, Carlos Julio
author_facet Amariles, Pedro
Granados, Johan
Ceballos, Mauricio
Montoya, Carlos Julio
author_sort Amariles, Pedro
collection PubMed
description The infection by the new coronavirus (SARS-CoV-2) has taken the dimension of a pandemic, affecting more than 160 countries in a few weeks. In Colombia, despite the implementation of the rules established by the national government, exists an elevate concern both for mortality and for the limited capacity of the health system to respond effectively to the needs of patients infected. For Colombia, assuming a case fatality rate among people infected with SARS-CoV-2 of 0.6% (average data from the information reported for Latin American countries for March 18) (Table 1), the number of deaths, in one or two weeks, could be 16 and 243, respectively. These estimates differ markedly from those documented in countries such as Spain and Italy, in which COVID-19 case fatality rates exceed 8% (case of Italy) and from the percentage of patients who have required intensive care, which has ranged from 9% to 11% of patients in Mediterranean European countries. These differences could be explained due to: a) the percentage of the population at risk (individuals older than 60 years); b) a higher epidemiological exposure to viral respiratory infections associated with more frequent exposure to them, due to geographic and climatic conditions; c) less spread of the virus by location in the tropical zone; and d) earlier preventive measures to contain the spread of SARS-CoV-2 infection. Therefore, it is possible to establish that the situation in this country will be different from in European Mediterranean and that Colombia could have different endpoints from Spain and Italy.
format Online
Article
Text
id pubmed-7118674
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-71186742020-04-03 COVID-19 in Colombia endpoints. Are we different, like Europe? Amariles, Pedro Granados, Johan Ceballos, Mauricio Montoya, Carlos Julio Res Social Adm Pharm Article The infection by the new coronavirus (SARS-CoV-2) has taken the dimension of a pandemic, affecting more than 160 countries in a few weeks. In Colombia, despite the implementation of the rules established by the national government, exists an elevate concern both for mortality and for the limited capacity of the health system to respond effectively to the needs of patients infected. For Colombia, assuming a case fatality rate among people infected with SARS-CoV-2 of 0.6% (average data from the information reported for Latin American countries for March 18) (Table 1), the number of deaths, in one or two weeks, could be 16 and 243, respectively. These estimates differ markedly from those documented in countries such as Spain and Italy, in which COVID-19 case fatality rates exceed 8% (case of Italy) and from the percentage of patients who have required intensive care, which has ranged from 9% to 11% of patients in Mediterranean European countries. These differences could be explained due to: a) the percentage of the population at risk (individuals older than 60 years); b) a higher epidemiological exposure to viral respiratory infections associated with more frequent exposure to them, due to geographic and climatic conditions; c) less spread of the virus by location in the tropical zone; and d) earlier preventive measures to contain the spread of SARS-CoV-2 infection. Therefore, it is possible to establish that the situation in this country will be different from in European Mediterranean and that Colombia could have different endpoints from Spain and Italy. Elsevier Inc. 2021-01 2020-03-31 /pmc/articles/PMC7118674/ /pubmed/32265115 http://dx.doi.org/10.1016/j.sapharm.2020.03.013 Text en © 2020 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Amariles, Pedro
Granados, Johan
Ceballos, Mauricio
Montoya, Carlos Julio
COVID-19 in Colombia endpoints. Are we different, like Europe?
title COVID-19 in Colombia endpoints. Are we different, like Europe?
title_full COVID-19 in Colombia endpoints. Are we different, like Europe?
title_fullStr COVID-19 in Colombia endpoints. Are we different, like Europe?
title_full_unstemmed COVID-19 in Colombia endpoints. Are we different, like Europe?
title_short COVID-19 in Colombia endpoints. Are we different, like Europe?
title_sort covid-19 in colombia endpoints. are we different, like europe?
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7118674/
https://www.ncbi.nlm.nih.gov/pubmed/32265115
http://dx.doi.org/10.1016/j.sapharm.2020.03.013
work_keys_str_mv AT amarilespedro covid19incolombiaendpointsarewedifferentlikeeurope
AT granadosjohan covid19incolombiaendpointsarewedifferentlikeeurope
AT ceballosmauricio covid19incolombiaendpointsarewedifferentlikeeurope
AT montoyacarlosjulio covid19incolombiaendpointsarewedifferentlikeeurope